Yufeng Ningxin for High Blood Pressure in Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, phase 4 trial compares Yufeng Ningxin tablets to placebo in adults with newly diagnosed or treated hypertension. Participants must have specific seated and ambulatory blood pressure criteria and undergo a 2-week washout of current antihypertensives. The study aims to determine the safety and efficacy of the traditional Chinese medicine as an add-on or alternative option. The trial is conducted at multiple Beijing hospitals under standard clinical research procedures. Outcomes will include blood pressure changes and safety assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female participants aged 18-65 years;
2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;
3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.

Exclusion Criteria:

1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);
2. Orthostatic hypotension (symptomatic or asymptomatic);
3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;
4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);
5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;
6. Severe hepatic or renal diseases (ALT \>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \<30 mL/min/1.73 m2);
7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\>9.0%);
8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \[TIA\]);
9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;
10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;
11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;
12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;
13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;
14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);
15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;
16. Participants preparing for or under pregnancy and/or lactation;
17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);
18. Other conditions deemed inappropriate for participation by the investigators.

Where it's running

• Beijing Anzhen Hospital
  Beijing, China Recruiting
• Chinese PLA General Hospital
  Beijing, China Recruiting
• Fuwai Hospital, Chinese Academy of Medical Sciences
  Beijing, China Recruiting
• Peking University First Hospital
  Beijing, China Recruiting
• The Second Affiliated Hospital of Dalian Medical University
  Dalian, China Recruiting
• Luohe Central Hospital
  Luohe, China Recruiting

Study contacts

• Study coordinator: Ruixue Yang, MD
• Email: yangruixue2020@163.com
• Phone: +86-10-81992130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using low-dose aspirin after preeclampsia to improve recovery

  This study is testing if taking low-dose aspirin for six months after having preeclampsia can help new moms recover better by improving their blood pressure and blood vessel function.

  Recruiting Phase 4 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT06281665

• IMB-guided health education to boost medication taking and blood pressure control in adults with hypertension

  This study tests a health-literacy program based on Information-Motivation-Behavioral Skills to help adults with hypertension who don’t take their medicines regularly to take them more consistently and better control their blood pressure.

  Recruiting at 8 sites Bahir Dar University · Ādēt and 7 other locations · NCT07894068

• Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF

  This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.

  Recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario · NCT07893821

• Hypertension: Does Education Help Patients Manage Blood Pressure Better?

  This study tests whether structured patient education improves blood pressure control and self-management in adults with hypertension who speak Turkish.

  Recruiting Inonu University · Batman, Center · NCT07890090

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Long-term GW906 treatment for people with essential hypertension

  This trial tests whether long-term GW906 injections are safe and effective for adults with essential hypertension who completed an earlier GW906 study.

  Recruiting Shenzhen Salubris Pharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT07879755

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.